Anlon Healthcare
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
Anlon Healthcare corrected the shareholding percentages it expected to acquire in Apiqo Organics and Bizotic Lifescience to 44.94% and 47.41%, respectively, from 32.52% and 43.33%. The proposed acquisitions remained structured as non-cash share swaps, valued at about ₹116.52 crore for AOPL and ₹36.78 crore for BLPL, with up to 8.59 crore Anlon shares to be issued at ₹17.85 each. AOPL and BLPL reported FY26 turnover of ₹72.54 crore and ₹31.27 crore, respectively, and both transactions were subject to approvals and expected to be completed within 90 days. Anlon's consolidated FY26 revenue was ₹172.22 crore, while standalone Q1 FY27 revenue was ₹30.98 crore.
Powered by Tijori
Anlon Healthcare corrected the shareholding percentages it expected to acquire in Apiqo Organics and Bizotic Lifescience to 44.94% and 47.41%, respectively, from 32.52% and 43.33%. The proposed acquisitions remained structured as non-cash share swaps, valued at about ₹116.52 crore for AOPL and ₹36.78 crore for BLPL, with up to 8.59 crore Anlon shares to be issued at ₹17.85 each. AOPL and BLPL reported FY26 turnover of ₹72.54 crore and ₹31.27 crore, respectively, and both transactions were subject to approvals and expected to be completed within 90 days. Anlon's consolidated FY26 revenue was ₹172.22 crore, while standalone Q1 FY27 revenue was ₹30.98 crore.
Powered by Tijori
Anlon Healthcare executed share-swap agreements to acquire up to 32.52% of Apiqo Organics and 43.33% of Bizotic Lifescience for aggregate consideration of about ₹153.3 crore. It proposed issuing up to 8.59 crore new equity shares at ₹17.85 each, subject to approvals and acceptance by the target shareholders, with no cash consideration expected. Apiqo, which manufactures pharmaceutical intermediates and industrial and fine chemicals, reported FY26 turnover of ₹72.5 crore, while Bizotic, an API and contract research and manufacturing business, reported ₹31.3 crore. Anlon's consolidated FY26 revenue was ₹172.2 crore and profit after tax was ₹29.1 crore after an acquisition-led expansion of the group.
Powered by Tijori
Anlon Healthcare executed share-swap agreements to acquire up to 32.52% of Apiqo Organics and 43.33% of Bizotic Lifescience for aggregate consideration of about ₹153.3 crore. It proposed issuing up to 8.59 crore new equity shares at ₹17.85 each, subject to approvals and acceptance by the target shareholders, with no cash consideration expected. Apiqo, which manufactures pharmaceutical intermediates and industrial and fine chemicals, reported FY26 turnover of ₹72.5 crore, while Bizotic, an API and contract research and manufacturing business, reported ₹31.3 crore. Anlon's consolidated FY26 revenue was ₹172.2 crore and profit after tax was ₹29.1 crore after an acquisition-led expansion of the group.
Powered by Tijori
March 6 (Reuters) - Anlon Healthcare Ltd ANLN.NS:
APPROVES ISSUE OF BONUS SHARES IN THE RATIO OF 1:1
SUB-DIVISION OF EACH SHARE INTO 5 SHARES
Source text: ID:nnAZN4SJW7D
Further company coverage: ANLN.NS
(([email protected];;))
March 6 (Reuters) - Anlon Healthcare Ltd ANLN.NS:
APPROVES ISSUE OF BONUS SHARES IN THE RATIO OF 1:1
SUB-DIVISION OF EACH SHARE INTO 5 SHARES
Source text: ID:nnAZN4SJW7D
Further company coverage: ANLN.NS
(([email protected];;))
Feb 9 (Reuters) - Anlon Healthcare Ltd ANLN.NS:
ANLON HEALTHCARE LTD - APPOINTMENT OF NAIMISH DILIPBHAI BHATT AS CFO
Source text: ID:nNSE7bv26J
Further company coverage: ANLN.NS
(([email protected];))
Feb 9 (Reuters) - Anlon Healthcare Ltd ANLN.NS:
ANLON HEALTHCARE LTD - APPOINTMENT OF NAIMISH DILIPBHAI BHATT AS CFO
Source text: ID:nNSE7bv26J
Further company coverage: ANLN.NS
(([email protected];))
** Shares of Anlon Healthcare ANLN.NS rise 6.3% to 142.99 rupees
** Pharma co says it has developed two new anti-malarial products, Artemether and Lumefantrine
** Both to be launched in November
** Stock set to gain for fifth straight session
** ANLN up nearly 55% from trading debut open price September 3
(Reporting by Vijay Malkar)
(([email protected];))
** Shares of Anlon Healthcare ANLN.NS rise 6.3% to 142.99 rupees
** Pharma co says it has developed two new anti-malarial products, Artemether and Lumefantrine
** Both to be launched in November
** Stock set to gain for fifth straight session
** ANLN up nearly 55% from trading debut open price September 3
(Reporting by Vijay Malkar)
(([email protected];))
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
- Business
- Financials
- Share Price
- Shareholdings
What does Anlon Healthcare do?
Anlon Healthcare is a chemical manufacturing company, engaged in manufacturing of pharmaceutical intermediates and Active Pharmaceutical Ingredients (APIs), which are supplied to customers both in India and international markets. Its products span across the family of pharmaceutical intermediates, active pharmaceutical ingredients, nutraceutical APIs and ingredients for personal care and veterinary API. It is also engaged in custom API development, including the preparation and submission of regulatory Drug Master Files (DMFs) for Indian and global markets.
Who are the competitors of Anlon Healthcare?
Anlon Healthcare major competitors are Kronox Lab Sciences, Acutaas Chemicals, Supriya Lifescience. Market Cap of Anlon Healthcare is ₹769 Crs. While the median market cap of its peers are ₹6,376 Crs.
Is Anlon Healthcare financially stable compared to its competitors?
Anlon Healthcare seems to be less financially stable compared to its competitors. Altman Z score of Anlon Healthcare is 5.41 and is ranked 4 out of its 4 competitors.
Does Anlon Healthcare pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Anlon Healthcare latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Anlon Healthcare allocated its funds?
Companies resources are allocated to majorly unproductive assets like Accounts Receivable
How strong is Anlon Healthcare balance sheet?
Balance sheet of Anlon Healthcare is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Anlon Healthcare improving?
Yes, profit is increasing. The profit of Anlon Healthcare is ₹29.06 Crs for TTM, ₹20.52 Crs for Mar 2025 and ₹9.66 Crs for Mar 2024.
Is the debt of Anlon Healthcare increasing or decreasing?
The net debt of Anlon Healthcare is decreasing. Latest net debt of Anlon Healthcare is ₹39.29 Crs as of Mar-26. This is less than Mar-25 when it was ₹65.1 Crs.
Is Anlon Healthcare stock expensive?
Anlon Healthcare is not expensive. Latest PE of Anlon Healthcare is 26.47, while 3 year average PE is 32.67. Also latest EV/EBITDA of Anlon Healthcare is 14.19 while 3yr average is 22.61.
Has the share price of Anlon Healthcare grown faster than its competition?
There is not enough historical data for the companies share price.
Is the promoter bullish about Anlon Healthcare?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Anlon Healthcare is 52.68% and last quarter promoter holding is 52.68%.
Are mutual funds buying/selling Anlon Healthcare?
There is Insufficient data to gauge this.